Myelodysplastic Syndromes (MDS)
Amit K. Verma, M.B.B.S.
Institution
Albert Einstein College of Medicine
Physician Status
available for consultation
Primary Disease Area of Focus
Myelodysplastic Syndromes (MDS)
About
Amit K. Verma, MBBS, is a Professor in the Departments of Medicine (Oncology) and Development & Molecular Biology at Albert Einstein School of Medicine. Dr. Verma is the Director of the Division of Hemato-Oncology, Montefiore Department of Oncology. His primary area of research is in MDS.
Ryotaro Nakamura, MD
Institution
City of Hope
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
About
Ryotaro Nakamura, MD is Professor, Department of Hematology & Hematopoietic Cell Transplantation; Director, Center for Stem Cell Transplantation at City of Hope. Since joining City of Hope in 2002, Ryotaro Nakamura, M.D., has been at the forefront of leading-edge research in stem cell transplantation and development of cancer vaccines. Among his promising projects: A study indicating that bone marrow transplants may be effective in treating systemic mastocytosis, a rare blood disease with no known cure, and the use of vaccines to replace antivirals which can often spawn deadly infections. Dr
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience
Mutations in the tumor suppressor gene TP53 are detected in 5-10% of patients with acute myeloid leukemia acute myeloid leukemia: (
High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity
We examined the association between serum ferritin ferritin: (FER-i-tin) A protein inside of cells that stores iron for later use by your body. Sometimes ferritin is released into the blood.
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes
Allogeneic hematopoietic stem cell transplantation (HCT) remains the only potentially curative option for myelodysplastic syndromes myelodysplast
Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
Background: The lower-risk (low and intermediate-1 risk based on IPSS) myelodysplastic syndrome (MDS) has a negative impact on patients' health-related quality of life (HRQoL). Patient Reported Outcomes (PROs) instruments, which are used to collect patients' HRQoL data, should have established content validity in the target population to ensure that the instrument is comprehensive and comprehensible.